227 related articles for article (PubMed ID: 27126178)
1. Small molecules that allosterically inhibit p21-activated kinase activity by binding to the regulatory p21-binding domain.
Kim DJ; Choi CK; Lee CS; Park MH; Tian X; Kim ND; Lee KI; Choi JK; Ahn JH; Shin EY; Shin I; Kim EG
Exp Mol Med; 2016 Apr; 48(4):e229. PubMed ID: 27126178
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of p21-activated kinases (PAKs).
Rudolph J; Crawford JJ; Hoeflich KP; Wang W
J Med Chem; 2015 Jan; 58(1):111-29. PubMed ID: 25415869
[TBL] [Abstract][Full Text] [Related]
3. p21-Activated kinase inhibitors: a patent review.
Crawford JJ; Hoeflich KP; Rudolph J
Expert Opin Ther Pat; 2012 Mar; 22(3):293-310. PubMed ID: 22404134
[TBL] [Abstract][Full Text] [Related]
4. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase.
Deacon SW; Beeser A; Fukui JA; Rennefahrt UE; Myers C; Chernoff J; Peterson JR
Chem Biol; 2008 Apr; 15(4):322-31. PubMed ID: 18420139
[TBL] [Abstract][Full Text] [Related]
5. The subcellular localization of type I p21-activated kinases is controlled by the disordered variable region and polybasic sequences.
Sun X; Su VL; Calderwood DA
J Biol Chem; 2019 Sep; 294(39):14319-14332. PubMed ID: 31391252
[TBL] [Abstract][Full Text] [Related]
6. FRAX597, a small molecule inhibitor of the p21-activated kinases, inhibits tumorigenesis of neurofibromatosis type 2 (NF2)-associated Schwannomas.
Licciulli S; Maksimoska J; Zhou C; Troutman S; Kota S; Liu Q; Duron S; Campbell D; Chernoff J; Field J; Marmorstein R; Kissil JL
J Biol Chem; 2013 Oct; 288(40):29105-14. PubMed ID: 23960073
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation-dependent activity-based conformational changes in P21-activated kinase family members and screening of novel ATP competitive inhibitors.
Gul M; Fakhar M; Najumuddin ; Rashid S
PLoS One; 2019; 14(11):e0225132. PubMed ID: 31738805
[TBL] [Abstract][Full Text] [Related]
8. P21 activated kinase signaling in cancer.
Rane CK; Minden A
Semin Cancer Biol; 2019 Feb; 54():40-49. PubMed ID: 29330094
[TBL] [Abstract][Full Text] [Related]
9. p21-activated kinase inhibitors.
Rudolph J; Crawford JJ; Hoeflich KP; Chernoff J
Enzymes; 2013; 34 Pt. B():157-80. PubMed ID: 25034104
[TBL] [Abstract][Full Text] [Related]
10. Identification of allosteric inhibitors of p21-activated kinase.
Viaud J; Peterson JR
Methods Mol Biol; 2012; 928():67-79. PubMed ID: 22956134
[TBL] [Abstract][Full Text] [Related]
11. PAK'n it in: identification of a selective PAK inhibitor.
Bokoch GM
Chem Biol; 2008 Apr; 15(4):305-6. PubMed ID: 18420134
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic Dbl, Cdc42, and p21-activated kinase form a ternary signaling intermediate through the minimum interactive domains.
Wang L; Zhu K; Zheng Y
Biochemistry; 2004 Nov; 43(46):14584-93. PubMed ID: 15544329
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of activation of Pak1 kinase by membrane localization.
Lu W; Mayer BJ
Oncogene; 1999 Jan; 18(3):797-806. PubMed ID: 9989831
[TBL] [Abstract][Full Text] [Related]
14. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently.
Viaud J; Peterson JR
Mol Cancer Ther; 2009 Sep; 8(9):2559-65. PubMed ID: 19723886
[TBL] [Abstract][Full Text] [Related]
15. CDC42 binds PAK4 via an extended GTPase-effector interface.
Ha BH; Boggon TJ
Proc Natl Acad Sci U S A; 2018 Jan; 115(3):531-536. PubMed ID: 29295922
[TBL] [Abstract][Full Text] [Related]
16. Development of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.
Ma Y; McCarty SK; Kapuriya NP; Brendel VJ; Wang C; Zhang X; Jarjoura D; Saji M; Chen CS; Ringel MD
J Clin Endocrinol Metab; 2013 Aug; 98(8):E1314-22. PubMed ID: 23709653
[TBL] [Abstract][Full Text] [Related]
17. p21-activated kinase 1 activity is required for histone H3 Ser
Zhang N; Li X; Liu X; Cao Y; Chen D; Liu X; Wang Q; Du J; Weng J; Ma W
Reprod Fertil Dev; 2017 Jul; 29(7):1287-1296. PubMed ID: 27166635
[TBL] [Abstract][Full Text] [Related]
18. Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity.
Song PL; Wang G; Su Y; Wang HX; Wang J; Li F; Cheng MS
Bioorg Chem; 2019 Oct; 91():103168. PubMed ID: 31400553
[TBL] [Abstract][Full Text] [Related]
19. 2-amino-N-{4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl} acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase.
Porchia LM; Guerra M; Wang YC; Zhang Y; Espinosa AV; Shinohara M; Kulp SK; Kirschner LS; Saji M; Chen CS; Ringel MD
Mol Pharmacol; 2007 Nov; 72(5):1124-31. PubMed ID: 17673571
[TBL] [Abstract][Full Text] [Related]
20. Rho family GTPase signaling through type II p21-activated kinases.
Chetty AK; Ha BH; Boggon TJ
Cell Mol Life Sci; 2022 Nov; 79(12):598. PubMed ID: 36401658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
